Search

Your search keyword '"Gerth Van Wijk, Roy"' showing total 443 results
Start Over Author "Gerth Van Wijk, Roy"
443 results on '"Gerth Van Wijk, Roy"'

2. Allergy education and training for physicians

Author

Barker, Sally, Daniels, Lydia, Chang, Yoon-Seok, Chikovani, Tinatin, DunnGalvin, Audrey, Gerdts, Jennifer D., Gerth Van Wijk, Roy, Gibbs, Trevor, Villarreal Gonzalez, Rosalaura V., Guzman-Avilan, Rosa I., Hanna, Heather, Hossny, Elham, Kolotilina, Anastasia, Ortega Martell, José Antonio, Pacharn, Punchama, de Lira Quezada, Cindy E., Sibanda, Elopy, Stukus, David, Tham, Elizabeth Huiwen, Venter, Carina, Gonzalez-Diaz, Sandra N., Levin, Michael E., Martin, Bryan, Warner, John O., and Munblit, Daniel

Published
2021
Full Text
View/download PDF

3. Harmonizing allergy care–integrated care pathways and multidisciplinary approaches

Author

Daniels, Lydia, Barker, Sally, Chang, Yoon-Seok, Chikovani, Tinatin, DunnGalvin, Audrey, Gerdts, Jennifer D., Gerth Van Wijk, Roy, Gibbs, Trevor, Villarreal-Gonzalez, Rosalaura V., Guzman-Avilan, Rosa I., Hanna, Heather, Hossny, Elham, Kolotilina, Anastasia, Ortega Martell, José Antonio, Pacharn, Punchama, de Lira Quezada, Cindy E., Sibanda, Elopy, Stukus, David, Tham, Elizabeth Huiwen, Venter, Carina, Gonzalez-Diaz, Sandra N., Levin, Michael E., Martin, Bryan, Munblit, Daniel, and Warner, John O.

Published
2021
Full Text
View/download PDF

4. Greenhouse Workers

Author

Gerth van Wijk, Roy, Liu, Liu, de Jong, Nicolette W., John, Swen Malte, editor, Johansen, Jeanne Duus, editor, Rustemeyer, Thomas, editor, Elsner, Peter, editor, and Maibach, Howard I., editor

Published
2020
Full Text
View/download PDF

6. IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position paper

Author

Ansotegui, Ignacio J., Melioli, Giovanni, Canonica, Giorgio Walter, Caraballo, Luis, Villa, Elisa, Ebisawa, Motohiro, Passalacqua, Giovanni, Savi, Eleonora, Ebo, Didier, Gómez, R. Maximiliano, Luengo Sánchez, Olga, Oppenheimer, John J., Jensen-Jarolim, Erika, Fischer, David A., Haahtela, Tari, Antila, Martti, Bousquet, Jean J., Cardona, Victoria, Chiang, Wen Chin, Demoly, Pascal M., DuBuske, Lawrence M., Ferrer Puga, Marta, Gerth van Wijk, Roy, González Díaz, Sandra Nora, Gonzalez-Estrada, Alexei, Jares, Edgardo, Kalpaklioğlu, Ayse Füsun, Kase Tanno, Luciana, Kowalski, Marek L., Ledford, Dennis K., Monge Ortega, Olga Patricia, Morais Almeida, Mário, Pfaar, Oliver, Poulsen, Lars K., Pawankar, Ruby, Renz, Harald E., Romano, Antonino G., Rosário Filho, Nelson A., Rosenwasser, Lanny, Sánchez Borges, Mario A., Scala, Enrico, Senna, Gian-Enrico, Sisul, Juan Carlos, Tang, Mimi L.K., Thong, Bernard Yu-Hor, Valenta, Rudolf, Wood, Robert A., and Zuberbier, Torsten

Published
2020
Full Text
View/download PDF

7. Comparison of skin prick test and prick-to-prick test with fruits and vegetables in the diagnosis of food allergy

Author

Terlouw, Severina, van Boven, Frank E., Borsboom-van Zonneveld, Monika, de Graaf-in ’t Veld, Tineke, Gerth van Wijk, Roy, van Daele, Paul L.A., van Maaren, Maurits S., Kuijpers, Jac H.S.A.M., Veenbergen, Sharon, de Jong, Nicolette W., Terlouw, Severina, van Boven, Frank E., Borsboom-van Zonneveld, Monika, de Graaf-in ’t Veld, Tineke, Gerth van Wijk, Roy, van Daele, Paul L.A., van Maaren, Maurits S., Kuijpers, Jac H.S.A.M., Veenbergen, Sharon, and de Jong, Nicolette W.

Abstract

Introduction: Prick-to-prick (PTP) test with fresh food is accepted as a reliable tool for measuring sensitization to fruits and vegetables. Not all fruits and vegetables are available throughout the year. The objective of this study was to investigate whether skin prick test (SPT) performed with frozen juice of fruits and vegetables (FJFV) is a good alternative to PTP tests performed with fresh fruits and vegetables (FFV). Methods: Adult patients suspected of having a food allergy to fruits and/or vegetables were included. A questionnaire was used to score symptoms after consumption of apple, kiwi, peach, tomato, and carrot. SPTs with FJFV, and PTP tests with FFV were performed. Intra-class correlation coefficients (ICC) between the SPT and PTP test results were calculated. The sensitivity and specificity of both diagnostic tests towards food allergen specific symptoms (FASS) were calculated. Results: Thirty-six patients were included. FASS was positive in 75% for apple, 53% for kiwi, 44% for peach, 25% for tomato, and 22% for carrot. ICC between SPT and PTP test results were moderate for apple (0.72) and kiwi (0.71), strong for peach (0.75) and tomato (0.89), and very strong for carrot (0.94). Sensitivity was equal for the SPT and PTP tests for apple (0.93), peach (0.81), and carrot (1.00), and comparable for kiwi (0.50 resp. 0.70), and tomato (0.44 resp. 0.56). Specificity was equal for apple (0.33), peach (0.15), and carrot (0.41), and comparable for kiwi (0.29 resp. 0.21) and tomato (0.80 resp. 0.72). Conclusions: Results of SPT with FJFV and PTP test with FFV are comparable. SPT with FJFV is a good alternative in the daily practice of the allergists.

Published
2024

8. Safety and efficacy of immunotherapy with the recombinant B-cell epitope–based grass pollen vaccine BM32

Author

Niederberger, Verena, Neubauer, Angela, Gevaert, Philippe, Zidarn, Mihaela, Worm, Margitta, Aberer, Werner, Malling, Hans Jørgen, Pfaar, Oliver, Klimek, Ludger, Pfützner, Wolfgang, Ring, Johannes, Darsow, Ulf, Novak, Natalija, Gerth van Wijk, Roy, Eckl-Dorna, Julia, Focke-Tejkl, Margarete, Weber, Milena, Müller, Hans-Helge, Klinger, Joachim, Stolz, Frank, Breit, Nora, Henning, Rainer, and Valenta, Rudolf

Published
2018
Full Text
View/download PDF

10. Genome-wide association study and meta-analysis in multiple populations identifies new loci for peanut allergy and establishes C11orf30/EMSY as a genetic risk factor for food allergy

Author

Asai, Yuka, Eslami, Aida, van Ginkel, C. Dorien, Akhabir, Loubna, Wan, Ming, Ellis, George, Ben-Shoshan, Moshe, Martino, David, Ferreira, Manuel A., Allen, Katrina, Mazer, Bruce, de Groot, Hans, de Jong, Nicolette W., Gerth van Wijk, Roy N., Dubois, Anthony E.J., Chin, Rick, Cheuk, Stephen, Hoffman, Joshua, Jorgensen, Eric, Witte, John S., Melles, Ronald B., Hong, Xiumei, Wang, Xiaobin, Hui, Jennie, Musk, Arthur W. (Bill), Hunter, Michael, James, Alan L., Koppelman, Gerard H., Sandford, Andrew J., Clarke, Ann E., and Daley, Denise

Published
2018
Full Text
View/download PDF

13. International consensus (ICON) on: clinical consequences of mite hypersensitivity, a global problem

Author

Sánchez-Borges, Mario, Fernandez-Caldas, Enrique, Thomas, Wayne R., Chapman, Martin D., Lee, Bee Wah, Caraballo, Luis, Acevedo, Nathalie, Chew, Fook Tim, Ansotegui, Ignacio J., Behrooz, Leili, Phipatanakul, Wanda, Gerth van Wijk, Roy, Pascal, Demoly, Rosario, Nelson, Ebisawa, Motohiro, Geller, Mario, Quirce, Santiago, Vrtala, Susanne, Valenta, Rudolf, Ollert, Markus, Canonica, Giorgio Walter, Calderón, Moises A., Barnes, Charles S., Custovic, Adnan, Benjaponpitak, Suwat, and Capriles-Hulett, Arnaldo

Published
2017
Full Text
View/download PDF

15. Correction: Inflammatory and tolerogenic myeloid cells determine outcome following human allergen challenge

Author

Voskamp, Astrid L., primary, Tak, Tamar, additional, Gerdes, Maarten L., additional, Menafra, Roberta, additional, Duijster, Ellen, additional, Jochems, Simon P., additional, Kielbasa, Szymon M., additional, Kormelink, Tom Groot, additional, Stam, Koen A., additional, van Hengel, Oscar R.J., additional, de Jong, Nicolette W., additional, Hendriks, Rudi W., additional, Kloet, Susan L., additional, Yazdanbakhsh, Maria, additional, de Jong, Esther C., additional, Gerth van Wijk, Roy, additional, and Smits, Hermelijn H., additional

Published
2023
Full Text
View/download PDF

16. Standardization of clinical outcomes used in allergen immunotherapy in allergic asthma: An EAACI position paper

Author

Kappen, Jasper, primary, Diamant, Zuzana, additional, Agache, Ioana, additional, Bonini, Matteo, additional, Bousquet, Jean, additional, Canonica, G. Walter, additional, Durham, Stephen R., additional, Guibas, George V., additional, Hamelmann, Eckard, additional, Jutel, Marek, additional, Papadopoulos, Nikolaos G., additional, Roberts, Graham, additional, Shamji, Mohamed H., additional, Zieglmayer, Petra, additional, Gerth van Wijk, Roy, additional, and Pfaar, Oliver, additional

Published
2023
Full Text
View/download PDF

17. Inflammatory and tolerogenic myeloid cells determine outcome following human allergen challenge

Author

Voskamp, Astrid L., primary, Tak, Tamar, additional, Gerdes, Maarten L., additional, Menafra, Roberta, additional, Duijster, Ellen, additional, Jochems, Simon P., additional, Kielbasa, Szymon M., additional, Kormelink, Tom Groot, additional, Stam, Koen A., additional, van Hengel, Oscar R.J., additional, de Jong, Nicolette W., additional, Hendriks, Rudi W., additional, Kloet, Susan L., additional, Yazdanbakhsh, Maria, additional, de Jong, Esther C., additional, Gerth van Wijk, Roy, additional, and Smits, Hermelijn H., additional

Published
2023
Full Text
View/download PDF

18. MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis

Author

Aberer, Werner, Adachi, Mitsuru, Agache, Ioana, Akdis, Cezmi, Akdis, Mubeccel, Annesi-Maesano, Isabella, Ansotegui, Ignacio J., Anto, Josep M., Arshad, S. Hasan, Baiardini, Ilaria, Baigenzhin, Abay K., Barbara, Cristina, Bateman, Eric D., Beghé, Bianca, Bel, Elisabeth H., Ben Kheder, Ali, Bennoor, Kazi S., Benson, Michael, Bernstein, David, Michael, Bewick, Thomas, Bieber, Bindslev-Jensen, Carsten, Bjermer, Leif, Blain, Hubert, Boner, Attilio, Bonini, Matteo, Bonini, Sergio, Bosse, Isabelle, Bouchard, Jacques, Boulet, Louis-Philippe, Bourret, Rodolphe A., Bousquet, Philippe J., Braido, Fulvio, Briggs, Andrew H., Brightling, Christopher E., Buhl, Roland, Burney, Peter, Bush, Andrew, Caballero-Fonseca, Fernando, Caimmi, Davide P., Camargos, Paulo, Camuzat, Thierry, Carlsen, Kai-Hakon, Carr, Warner, Casale, Thomas B., Sarabia, Alfonso Cepeda, Chatzi, Leda, Chen, Yuzhi, Chiron, Raphaël, Chkhartishvili, Ekaterine, Chuchalin, Alexander, Ciprandi, Georgio, Cirule, Ieva, Correia de Sousa, Jaime, Costa, David, Crooks, George, Custovic, Adnan, Dahlen, Sven-Erik, Darsow, Ulf, De Blay, Frédéric, De Manuel Keenoy, Esteban, Dedeu, Tony, Deleanu, Diana, Denburg, Judah, Didier, Alain, Dinh-Xuan, Anh-Tuan, Dokic, Dejan, Douagui, Habib B., Dubakiene, Ruta, Durham, Stephen, Dykewicz, Mark, El-Gamal, Yehia, Emuzyte, Regina, Fink-Wagner, Antje, Fiocchi, Alessandro, Forastiere, Francesco, Gamkrelidze, Amiran, Gemicioğlu, Bilun, Gereda, Jose E., Gerth van Wijk, Roy, Gotua, Maia, Grisle, Ineta, Guzmán, M. Antonieta, Haahtela, Tari, Heinrich, Joachim, Hellquist-Dahl, Birthe, Horak, Friedrich, Howarth, Peter H., Humbert, Marc, Hyland, Michael, Ivancevich, Juan-Carlos, Jares, Edgardo J., Johnston, Sebastian L., Jonquet, Olivier, Joos, Guy, Jung, Ki-Suck, Just, Jocelyne, Jutel, Marek, Kaidashev, Igor P., Khaitov, Musa, Kalayci, Omer, Kalyoncu, Fuat, Keith, Paul, Khaltaev, Nikolai, Kleine-Tebbe, Jorg, Klimek, Ludger, N'Goran, Bernard Koffi, Kolek, Vitezlav, Koppelman, Gerard H., Kowalski, Marek, Kull, Inger, Kvedariene, Violeta, Lambrecht, Bart, Lau, Susanne, Laune, Daniel, Le Thi Tuyet, Lan, Li, Jing, Lieberman, Phillipe, Lipworth, Brian J., Renaud, Louis, Magard, Yves, Magnan, Antoine, Mahboub, Bassam, Majer, Ivan, Makela, Mika, Manning, Peter J., Masjedi, Mohamad R., Maurer, Marcus, Mavale-Manuel, Sandra, Melén, Erik, Melo-Gomes, Elisabete, Mercier, Jacques, Merk, Hans, Miculinic, Neven, Mihaltan, Florin, Milenkovic, Branislava, Mohammad, Yousser, Molimard, Mathieu, Momas, Isabelle, Montilla-Santana, Anna, Morais-Almeida, Mario, Mösges, Ralph, Nadif, Rachel, Namazova-Baranova, Leyla, Neffen, Hugo, Nekam, Kristof, Neou, Angelos, Niggemann, Bodo, Nyembue, Dieudonné, O'Hehir, Robyn, Ohta, Ken, Okamoto, Yoshitaka, Okubo, Kim, Ouedraogo, Solange, Paggiaro, Pier-Luigi, Pali-Schöll, Isabella, Palmer, Stephen, Panzner, Petr, Papi, Alberto, Park, Hae-Sim, Pavord, Ian, Pawankar, Ruby, Pfaar, Oliver, Picard, Robert, Pigearias, Bernard, Pin, Isabelle, Plavec, Davor, Pohl, Wolfgang, Popov, Todor, Postma, Dirkje S., Potter, Paul, Poulsen, Lars K., Rabe, Klaus F., Raciborski, Filip, Pontal, Françoise Radier, Reitamo, Sakari, Repka-Ramirez, Maria-Susana, Robalo-Cordeiro, Carlos, Roberts, Graham, Rodenas, Francisco, Rolland, Christine, Rodriguez, Miguel Roman, Romano, Antonino, Rosado-Pinto, José, Rosario, Nelson A., Rosenwasser, Larry, Rottem, Menachem, Sanchez-Borges, Mario, Sastre-Dominguez, Joaquim, Schmid-Grendelmeier, Peter, Serrano, Eli, Simons, F. Estelle R., Sisul, Juan-Carlos, Skrindo, Ingebjorg, Smit, Henriette A., Solé, Dirceu, Sooronbaev, Talant, Spranger, Otto, Stelmach, Rafael, Strandberg, Timo, Sunyer, Jordi, Thijs, Carel, Todo-Bom, Ana-Maria, Triggiani, Massimo, Valenta, Rudolf, Valero, Antonio L., van Hage, Marianne, Vandenplas, Olivier, Vezzani, Giorgio, Vichyanond, Pakit, Viegi, Giovanni, Wagenmann, Martin, Wahn, Ulrich, De Yun, Wang, Williams, Denis, Wright, John, Yawn, Barbara P., Yiallouros, Panayiotis, Yusuf, Osman M., Zar, Heather J., Zernotti, Mario, Zhang, Luo, Zhong, Nanshan, Zidarn, Mihaela, Bousquet, Jean, Schünemann, Holger J., Hellings, Peter W., Arnavielhe, Sylvie, Bachert, Claus, Bedbrook, Anna, Bergmann, Karl-Christian, Bosnic-Anticevich, Sinthia, Brozek, Jan, Calderon, Moises, Canonica, G. Walter, Chavannes, Niels H., Cox, Linda, Chrystyn, Henry, Cruz, Alvaro A., Dahl, Ronald, De Carlo, Giuseppe, Demoly, Pascal, Devillier, Phillipe, Dray, Gérard, Fletcher, Monica, Fokkens, Wytske J., Fonseca, Joao, Gonzalez-Diaz, Sandra N., Grouse, Lawrence, Keil, Thomas, Kuna, Piotr, Larenas-Linnemann, Désirée, Lodrup Carlsen, Karin C., Meltzer, Eli O., Mullol, Jaoquim, Muraro, Antonella, Naclerio, Robert N., Palkonen, Susanna, Papadopoulos, Nikolaos G., Passalacqua, Giovanni, Price, David, Ryan, Dermot, Samolinski, Boleslaw, Scadding, Glenis K., Sheikh, Aziz, Spertini, François, Valiulis, Arunas, Valovirta, Erkka, Walker, Samantha, Wickman, Magnus, Yorgancioglu, Arzu, and Zuberbier, Torsten

Published
2016
Full Text
View/download PDF

20. International Consensus on Allergen Immunotherapy II: Mechanisms, standardization, and pharmacoeconomics

Author

Jutel, Marek, Agache, Ioana, Bonini, Sergio, Burks, A. Wesley, Calderon, Moises, Canonica, Walter, Cox, Linda, Demoly, Pascal, Frew, Antony J., O'Hehir, Robyn, Kleine-Tebbe, Jörg, Muraro, Antonella, Lack, Gideon, Larenas, Désirée, Levin, Michael, Martin, Bryan L., Nelson, Harald, Pawankar, Ruby, Pfaar, Oliver, van Ree, Ronald, Sampson, Hugh, Sublett, James L., Sugita, Kazunari, Du Toit, George, Werfel, Thomas, Gerth van Wijk, Roy, Zhang, Luo, Akdis, Mübeccel, and Akdis, Cezmi A.

Published
2016
Full Text
View/download PDF

23. Standardization of clinical outcomes used in allergen immunotherapy in allergic asthma:An EAACI position paper

Author

Kappen, Jasper, Diamant, Zuzana, Agache, Ioana, Bonini, Matteo, Bousquet, Jean, Canonica, G. Walter, Durham, Stephen R., Guibas, George V., Hamelmann, Eckard, Jutel, Marek, Papadopoulos, Nikolaos G., Roberts, Graham, Shamji, Mohamed H., Zieglmayer, Petra, Gerth van Wijk, Roy, Pfaar, Oliver, Kappen, Jasper, Diamant, Zuzana, Agache, Ioana, Bonini, Matteo, Bousquet, Jean, Canonica, G. Walter, Durham, Stephen R., Guibas, George V., Hamelmann, Eckard, Jutel, Marek, Papadopoulos, Nikolaos G., Roberts, Graham, Shamji, Mohamed H., Zieglmayer, Petra, Gerth van Wijk, Roy, and Pfaar, Oliver

Abstract

Introduction: In allergic asthma patients, one of the more common phenotypes might benefit from allergen immunotherapy (AIT) as add-on intervention to pharmacological treatment. AIT is a treatment with disease-modifying modalities, the evidence for efficacy is based on controlled clinical trials following standardized endpoint measures. However, so far there is a lack of a consensus for asthma endpoints in AIT trials. The aim of a task force (TF) of the European Academy of Allergy and Clinical Immunology (EAACI) is evaluating several outcome measures for AIT in allergic asthma. Methods: The following domains of outcome measures in asthmatic patients have been evaluated for this position paper (PP): (i) exacerbation rate, (ii) lung function, (iii) ICS withdrawal, (iv) symptoms and rescue medication use, (v) questionnaires (PROMS), (vi) bronchial/nasal provocation, (vii) allergen exposure chambers (AEC) and (viii) biomarkers. Results: Exacerbation rate can be used as a reliable objective primary outcome; however, there is limited evidence due to different definitions of exacerbation. The time after ICS withdrawal to first exacerbation is considered a primary outcome measure. Besides, the advantages and disadvantages and clinical implications of further domains of asthma endpoints in AIT trials are elaborated in this PP. Conclusion: This EAACI-PP aims to highlight important aspects of current asthma measures by critically evaluating their applicability for controlled trials of AIT.

Published
2023

24. Reactions to peanut at first introduction in infancy are associated with age ≥8 months and severity of eczema

Author

Verhoeven, Dirk H.J., Herpertz, Irene C.E.M., Hol, Jeroen, Klok, Ted, Fleuren, Suzanne P.M., Hendriks, Tom, Gerth van Wijk, Roy, de Groot, Hans, Verhoeven, Dirk H.J., Herpertz, Irene C.E.M., Hol, Jeroen, Klok, Ted, Fleuren, Suzanne P.M., Hendriks, Tom, Gerth van Wijk, Roy, and de Groot, Hans

Abstract

Background: Previous studies have shown the efficacy of the early introduction of peanut to prevent peanut allergy. Due to the exclusion of infants with sensitization to peanut, it remains unclear what the optimal timing of introduction is. Methods: The PeanutNL study was performed in 6 pediatric allergology centers in the Netherlands. Infants referred for the clinical early introduction of peanut to prevent peanut allergy underwent skin prick tests for peanut and an oral peanut challenge at a median age of 6 months. Results: One hundred sixty two of 707 infants (23%) who had never eaten peanut before were sensitized to peanut, of which 80 (49%) had wheals of >4 mm. Sixty seven of 707 infants (9.5%) had a positive oral challenge to peanut at first introduction. Multivariate analysis revealed that age (p <.001) and SCORAD eczema severity scores (p =.001) were significant risk factors. Introduction of peanut at ≥8 months in infants with moderate and severe eczema resulted in an increased risk (odds ratio 5.24 (p =.013) and 3.61 (p =.019), respectively) of having reactions to peanut as compared to introduction before 8 months. A family history of peanut allergy and previous reactions to egg were not identified as independent risk factors. Conclusion: These results suggest that peanut should be introduced before the age of 8 months to reduce the risk of reactions at first exposure in infants with moderate and severe eczema. Furthermore, since children with severe eczema have the highest risk of reactions, the clinical introduction of peanut should be considered, at the latest at the age of 7 months.

Published
2023

25. Inflammatory and tolerogenic myeloid cells determine outcome following human allergen challenge

Author

Voskamp, Astrid L., Tak, Tamar, Gerdes, Maarten L., Menafra, Roberta, Duijster, Ellen, Kielbasa, Szymon M., Kormelink, Tom Groot, Stam, Koen A., van Hengel, Oscar R.J., de Jong, Nicolette W., Hendriks, Rudi W., Kloet, Susan L., Yazdanbakhsh, Maria, de Jong, Esther C., Gerth van Wijk, Roy, Smits, Hermelijn H., Voskamp, Astrid L., Tak, Tamar, Gerdes, Maarten L., Menafra, Roberta, Duijster, Ellen, Kielbasa, Szymon M., Kormelink, Tom Groot, Stam, Koen A., van Hengel, Oscar R.J., de Jong, Nicolette W., Hendriks, Rudi W., Kloet, Susan L., Yazdanbakhsh, Maria, de Jong, Esther C., Gerth van Wijk, Roy, and Smits, Hermelijn H.

Abstract

Innate mononuclear phagocytic system (MPS) cells preserve mucosal immune homeostasis. We investigated their role at nasal mucosa following allergen challenge with house dust mite. We combined single-cell proteome and transcriptome profiling on nasal immune cells from nasal biopsies cells from 30 allergic rhinitis and 27 non-allergic subjects before and after repeated nasal allergen challenge. Biopsies of patients showed infiltrating inflammatory HLA-DRhi/CD14+ and CD16+ monocytes and proallergic transcriptional changes in resident CD1C+/CD1A+ conventional dendritic cells (cDC)2 following challenge. In contrast, non-allergic individuals displayed distinct innate MPS responses to allergen challenge: predominant infiltration of myeloid-derived suppressor cells (MDSC: HLA-DRlow/CD14+ monocytes) and cDC2 expressing inhibitory/tolerogenic transcripts. These divergent patterns were confirmed in ex vivo stimulated MPS nasal biopsy cells. Thus, we identified not only MPS cell clusters involved in airway allergic inflammation but also highlight novel roles for non-inflammatory innate MPS responses by MDSC to allergens in non-allergic individuals. Future therapies should address MDSC activity as treatment for inflammatory airway diseases.

Published
2023

26. Tolerance Induction in Cow’s Milk Allergic Children by Heated Cow’s Milk Protein:The iAGE Follow-Up Study

Author

van Boven, Frank E., Arends, Nicolette J.T., Sprikkelman, Aline B., Emons, Joyce A.M., Hendriks, Astrid I., van Splunter, Marloes, Schreurs, Marco W.J., Terlouw, Severina, Gerth van Wijk, Roy, Wichers, Harry J., Savelkoul, Huub F.J., van Neerven, R. J.Joost, Hettinga, Kasper A., de Jong, Nicolette W., van Boven, Frank E., Arends, Nicolette J.T., Sprikkelman, Aline B., Emons, Joyce A.M., Hendriks, Astrid I., van Splunter, Marloes, Schreurs, Marco W.J., Terlouw, Severina, Gerth van Wijk, Roy, Wichers, Harry J., Savelkoul, Huub F.J., van Neerven, R. J.Joost, Hettinga, Kasper A., and de Jong, Nicolette W.

Abstract

Accelerating the induction of tolerance to cow’s milk (CM) reduces the burden of cow’s milk allergy (CMA). In this randomised controlled intervention study, we aimed to investigate the tolerance induction of a novel heated cow milk protein, the iAGE product, in 18 children with CMA (diagnosed by a paedriatric allergist). Children who tolerated the iAGE product were included. The treatment group (TG: n = 11; mean age 12.8 months, SD = 4.7) consumed the iAGE product daily with their own diet, and the control group (CG: n = 7; mean age 17.6 months, SD = 3.2) used an eHF without any milk consumption. In each group, 2 children had multiple food allergies. The follow-up procedures consisted of a double-blind placebo-controlled food challenge (DBPCFC) with CM t = 0, t = 1 (8 months), t = 2 (16 months), and t = 3 (24 months). At t = 1, eight (73%) of 11 children in the TG had a negative DBPCFC, versus four out of seven (57%) in the CG (BayesFactor = 0.61). At t = 3, nine of the 11 (82%) children in the TG and five of seven (71%) in the CG were tolerant (BayesFactor = 0.51). SIgE for CM reduced from a mean of 3.41 kU/L (SD = 5.63) in the TG to 1.24 kU/L (SD = 2.08) at the end of intervention, respectively a mean of 2.58 (SD = 3.32) in the CG to 0.63 kU/L (SD = 1.06). Product-related AEs were not reported. CM was successfully introduced in all children with negative DBPCFC. We found a standardised, well-defined heated CM protein powder that is safe for daily OIT treatment in a selected group of children with CMA. However, the benefits of inducing tolerance were not observed.

Published
2023

27. Tolerance Induction in Cow’s Milk Allergic Children by Heated Cow’s Milk Protein : The iAGE Follow-Up Study

Author

van Boven, Frank E., Arends, Nicolette J.T., Sprikkelman, Aline B., Emons, Joyce A.M., Hendriks, Astrid I., van Splunter, Marloes, Schreurs, Marco W.J., Terlouw, Severina, Gerth van Wijk, Roy, Wichers, Harry J., Savelkoul, Huub F.J., van Neerven, R.J.J., Hettinga, Kasper A., de Jong, Nicolette W., van Boven, Frank E., Arends, Nicolette J.T., Sprikkelman, Aline B., Emons, Joyce A.M., Hendriks, Astrid I., van Splunter, Marloes, Schreurs, Marco W.J., Terlouw, Severina, Gerth van Wijk, Roy, Wichers, Harry J., Savelkoul, Huub F.J., van Neerven, R.J.J., Hettinga, Kasper A., and de Jong, Nicolette W.

Abstract

Accelerating the induction of tolerance to cow’s milk (CM) reduces the burden of cow’s milk allergy (CMA). In this randomised controlled intervention study, we aimed to investigate the tolerance induction of a novel heated cow milk protein, the iAGE product, in 18 children with CMA (diagnosed by a paedriatric allergist). Children who tolerated the iAGE product were included. The treatment group (TG: n = 11; mean age 12.8 months, SD = 4.7) consumed the iAGE product daily with their own diet, and the control group (CG: n = 7; mean age 17.6 months, SD = 3.2) used an eHF without any milk consumption. In each group, 2 children had multiple food allergies. The follow-up procedures consisted of a double-blind placebo-controlled food challenge (DBPCFC) with CM t = 0, t = 1 (8 months), t = 2 (16 months), and t = 3 (24 months). At t = 1, eight (73%) of 11 children in the TG had a negative DBPCFC, versus four out of seven (57%) in the CG (BayesFactor = 0.61). At t = 3, nine of the 11 (82%) children in the TG and five of seven (71%) in the CG were tolerant (BayesFactor = 0.51). SIgE for CM reduced from a mean of 3.41 kU/L (SD = 5.63) in the TG to 1.24 kU/L (SD = 2.08) at the end of intervention, respectively a mean of 2.58 (SD = 3.32) in the CG to 0.63 kU/L (SD = 1.06). Product-related AEs were not reported. CM was successfully introduced in all children with negative DBPCFC. We found a standardised, well-defined heated CM protein powder that is safe for daily OIT treatment in a selected group of children with CMA. However, the benefits of inducing tolerance were not observed.

Published
2023

29. International consensus on allergy immunotherapy

Author

Jutel, Marek, Agache, Ioana, Bonini, Sergio, Burks, A. Wesley, Calderon, Moises, Canonica, Walter, Cox, Linda, Demoly, Pascal, Frew, Antony J., O'Hehir, Robin, Kleine-Tebbe, Jörg, Muraro, Antonella, Lack, Gideon, Larenas, Désirée, Levin, Michael, Nelson, Harald, Pawankar, Ruby, Pfaar, Oliver, van Ree, Ronald, Sampson, Hugh, Santos, Alexandra F., Du Toit, George, Werfel, Thomas, Gerth van Wijk, Roy, Zhang, Luo, and Akdis, Cezmi A.

Published
2015
Full Text
View/download PDF

31. Tolerance Induction in Cow’s Milk Allergic Children by Heated Cow’s Milk Protein: The iAGE Follow-Up Study

Author

van Boven, Frank E., primary, Arends, Nicolette J. T., additional, Sprikkelman, Aline B., additional, Emons, Joyce A. M., additional, Hendriks, Astrid I., additional, van Splunter, Marloes, additional, Schreurs, Marco W. J., additional, Terlouw, Severina, additional, Gerth van Wijk, Roy, additional, Wichers, Harry J., additional, Savelkoul, Huub F. J., additional, van Neerven, R. J. Joost, additional, Hettinga, Kasper A., additional, and de Jong, Nicolette W., additional

Published
2023
Full Text
View/download PDF

32. Accelerating Tolerance Induction In Cow's Milk Allergic Children By Heated Cow's Milk Protein: The iAGE Follow-up Study.

Author

De Jong, Nicolette, primary, Arends, Nicolette, additional, Sprikkelman, Aline, additional, Emons, Joyce, additional, Hendriks, Astrid, additional, van Splunter, Marloes, additional, Schreurs, Marco, additional, Terlouw, Severina, additional, Pellis, LInette, additional, Gerth van Wijk, Roy, additional, Wichers, Harry, additional, Savelkoul, Huub, additional, van Neerven, Joost, additional, Hettinga, Kasper, additional, and van Boven, Frank, additional

Published
2023
Full Text
View/download PDF

35. Current state and future of pediatric allergology in Europe: A road map

Author

Tsilochristou, Olympia, Maggina, Paraskevi, Zolkipli, Zaraquiza, Sanchez Garcia, Silvia, Uysal, Pinar, Alvaro Lozano, Montserrat, Atanaskovic‐Markovic, Marina, Baghdasaryan, Astghik, Beyer, Kirsten, DuToit, George, Gerth van Wijk, Roy, Høst, Arne, OʼHourihane, Jonathan, Ingemann, Lars, Kivistö, Juho E., Lopes dos Santos, Jose Manuel, Melén, Erik, Muraro, Antonella, Nieto, Antonio, Pajno, Giovanni, Rose, Klaus, Réthy, Lagos A., Sackesen, Cansin, Schmid Grendelmeier, Peter, Valovirta, Erkka, Wickman, Magnus, Eigenmann, Philippe A., Wahn, Ulrich, and van der Poel, Lauri‐Ann

Published
2018
Full Text
View/download PDF

36. Effect of Varying Doses of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Exposure Among Patients With Peanut Sensitivity: A Randomized Clinical Trial

Author

Sampson, Hugh A., Shreffler, Wayne G., Yang, William H., Sussman, Gordon L., Brown-Whitehorn, Terri F., Nadeau, Kari C., Cheema, Amarjit S., Leonard, Stephanie A., Pongracic, Jacqueline A., Sauvage-Delebarre, Christine, Assa’ad, Amal H., de Blay, Frederic, Bird, J. Andrew, Tilles, Stephen A., Boralevi, Franck, Bourrier, Thierry, Hébert, Jacques, Green, Todd D., Gerth van Wijk, Roy, Knulst, André C., Kanny, Gisèle, Schneider, Lynda C., Kowalski, Marek L., and Dupont, Christophe

Published
2017
Full Text
View/download PDF

38. Development and validation of combined symptom-medication scores for allergic rhinitis*

Author

Sousa-Pinto, Bernardo, Azevedo, Luís Filipe, Jutel, Marek, Agache, Ioana, Canonica, G. Walter, Czarlewski, Wienczyslawa, Papadopoulos, Nikolaos G., Bergmann, Karl-Christian, Devillier, Philippe, Laune, Daniel, Klimek, Ludger, Anto, Aram, Anto, Josep M., Eklund, Patrik, Almeida, Rute, Bedbrook, Anna, Bosnic-Anticevich, Sinthia, Brough, Helen A., Brussino, Luisa, Cardona, Victoria, Casale, Thomas, Cecchi, Lorenzo, Charpin, Denis, Chivato, Tomás, Costa, Elisio M., Cruz, Alvaro A., Dramburg, Stephanie, Durham, Stephen R., De Feo, Giulia, Gerth van Wijk, Roy, Fokkens, Wystke J., Gemicioglu, Bilun, Haahtela, Tari, Illario, Maddalena, Ivancevich, Juan Carlos, Kvedariene, Violeta, Kuna, Piotr, Larenas-Linnemann, Désirée E., Makris, Michael, Mathieu-Dupas, Eve, Melén, Erik, Morais-Almeida, Mario, Mösges, Ralph, Mullol, Joaquim, Nadeau, Kari C., Pham-Thi, Nhân, O’Hehir, Robyn, Regateiro, Frederico S., Reitsma, Sietze, Samolinski, Boleslaw, Sheikh, Aziz, Stellato, Cristiana, Todo-Bom, Ana, Tomazic, Peter Valentin, Toppila-Salmi, Sanna, Valero, Antonio, Valiulis, Arunas, Ventura, Maria Teresa, Wallace, Dana, Waserman, Susan, Yorgancioglu, Arzu, De Vries, Govert, van Eerd, Michiel, Zieglmayer, Petra, Zuberbier, Torsten, Pfaar, Oliver, Almeida Fonseca, João, Bousquet, Jean, Sousa-Pinto, Bernardo, Azevedo, Luís Filipe, Jutel, Marek, Agache, Ioana, Canonica, G. Walter, Czarlewski, Wienczyslawa, Papadopoulos, Nikolaos G., Bergmann, Karl-Christian, Devillier, Philippe, Laune, Daniel, Klimek, Ludger, Anto, Aram, Anto, Josep M., Eklund, Patrik, Almeida, Rute, Bedbrook, Anna, Bosnic-Anticevich, Sinthia, Brough, Helen A., Brussino, Luisa, Cardona, Victoria, Casale, Thomas, Cecchi, Lorenzo, Charpin, Denis, Chivato, Tomás, Costa, Elisio M., Cruz, Alvaro A., Dramburg, Stephanie, Durham, Stephen R., De Feo, Giulia, Gerth van Wijk, Roy, Fokkens, Wystke J., Gemicioglu, Bilun, Haahtela, Tari, Illario, Maddalena, Ivancevich, Juan Carlos, Kvedariene, Violeta, Kuna, Piotr, Larenas-Linnemann, Désirée E., Makris, Michael, Mathieu-Dupas, Eve, Melén, Erik, Morais-Almeida, Mario, Mösges, Ralph, Mullol, Joaquim, Nadeau, Kari C., Pham-Thi, Nhân, O’Hehir, Robyn, Regateiro, Frederico S., Reitsma, Sietze, Samolinski, Boleslaw, Sheikh, Aziz, Stellato, Cristiana, Todo-Bom, Ana, Tomazic, Peter Valentin, Toppila-Salmi, Sanna, Valero, Antonio, Valiulis, Arunas, Ventura, Maria Teresa, Wallace, Dana, Waserman, Susan, Yorgancioglu, Arzu, De Vries, Govert, van Eerd, Michiel, Zieglmayer, Petra, Zuberbier, Torsten, Pfaar, Oliver, Almeida Fonseca, João, and Bousquet, Jean

Abstract

Background: Validated combined symptom-medication scores (CSMSs) are needed to investigate the effects of allergic rhinitis treatments. This study aimed to use real-life data from the MASK-air® app to generate and validate hypothesis- and data-driven CSMSs. Methods: We used MASK-air® data to assess the concurrent validity, test-retest reliability and responsiveness of one hypothesis-driven CSMS (modified CSMS: mCSMS), one mixed hypothesis- and data-driven score (mixed score), and several data-driven CSMSs. The latter were generated with MASK-air® data following cluster analysis and regression models or factor analysis. These CSMSs were compared with scales measuring (i) the impact of rhinitis on work productivity (visual analogue scale [VAS] of work of MASK-air®, and Work Productivity and Activity Impairment: Allergy Specific [WPAI-AS]), (ii) quality-of-life (EQ-5D VAS) and (iii) control of allergic diseases (Control of Allergic Rhinitis and Asthma Test [CARAT]). Results: We assessed 317,176 days of MASK-air® use from 17,780 users aged 16-90 years, in 25 countries. The mCSMS and the factor analyses-based CSMSs displayed poorer validity and responsiveness compared to the remaining CSMSs. The latter displayed moderate-to-strong correlations with the tested comparators, high test-retest reliability and moderate-to-large responsiveness. Among data-driven CSMSs, a better performance was observed for cluster analyses-based CSMSs. High accuracy (capacity of discriminating different levels of rhinitis control) was observed for the latter (AUC-ROC = 0.904) and for the mixed CSMS (AUC-ROC = 0.820). Conclusion: The mixed CSMS and the cluster-based CSMSs presented medium-high validity, reliability and accuracy, rendering them as candidates for primary endpoints in future rhinitis trials.

Published
2022
Full Text
View/download PDF

39. Proposal of 0.5 mg of protein/100 g of processed food as threshold for voluntary declaration of food allergen traces in processed food—A first step in an initiative to better inform patients and avoid fatal allergic reactions:A GA2LEN position paper

Author

Zuberbier, Torsten, Dörr, Tamara, Aberer, Werner, Alvaro, Montserrat, Angier, Elizabeth, Arasi, Stefania, Arshad, Hasan, Ballmer-Weber, Barbara, Bartra, Joan, Beck, Lisa, Bégin, Philippe, Bindslev-Jensen, Carsten, Bislimovska, Jovanka, Bousquet, Jean, Brockow, Knut, Bush, Andrew, Cianferoni, Antonella, Cork, Michael J., Custovic, Adnan, Darsow, Ulf, de Jong, Nicolette, Deleanu, Diana, Del Giacco, Stefano, Deschildre, Antoine, Dunn Galvin, Audrey, Ebisawa, Motohiro, Fernández-Rivas, Montserrat, Ferrer, Marta, Fiocchi, Alessandro, Gerth van Wijk, Roy, Gotua, Maia, Grimshaw, Kate, Grünhagen, Josefine, Heffler, Enrico, Hide, Michihiro, Hoffmann-Sommergruber, Karin, Incorvaia, Cristoforo, Janson, Christer, Malte John, Swen, Jones, Carla, Jutel, Marek, Katoh, Norito, Kendziora, Benjamin, Kinaciyan, Tamar, Knol, Edward, Kurbacheva, Oksana, Lau, Susanne, Loh, Richard, Lombardi, Carlo, Mäkelä, Mika, Marchisotto, Mary Jane, Makris, Michael, Maurer, Marcus, Meyer, Rosan, Mijakoski, Dragan, Minov, Jordan, Mullol, Joaquim, Nilsson, Caroline, Nowak–Wegrzyn, Anna, Nwaru, Bright I., Odemyr, Mikela, Pajno, Giovanni Battista, Paudel, Sushil, Papadopoulos, Nikolaos G., Renz, Harald, Ricci, Giampaolo, Ring, Johannes, Rogala, Barbara, Sampson, Hugh, Senna, Gianenrico, Sitkauskiene, Brigita, Smith, Peter Kenneth, Stevanovic, Katarina, Stoleski, Sasho, Szajewska, Hania, Tanaka, Akio, Todo-Bom, Ana, Topal, Fatih Alexander, Valovirta, Erkka, Van Ree, Ronald, Venter, Carina, Wöhrl, Stefan, Wong, Gary W.K., Zhao, Zuotao, Worm, Margitta, Zuberbier, Torsten, Dörr, Tamara, Aberer, Werner, Alvaro, Montserrat, Angier, Elizabeth, Arasi, Stefania, Arshad, Hasan, Ballmer-Weber, Barbara, Bartra, Joan, Beck, Lisa, Bégin, Philippe, Bindslev-Jensen, Carsten, Bislimovska, Jovanka, Bousquet, Jean, Brockow, Knut, Bush, Andrew, Cianferoni, Antonella, Cork, Michael J., Custovic, Adnan, Darsow, Ulf, de Jong, Nicolette, Deleanu, Diana, Del Giacco, Stefano, Deschildre, Antoine, Dunn Galvin, Audrey, Ebisawa, Motohiro, Fernández-Rivas, Montserrat, Ferrer, Marta, Fiocchi, Alessandro, Gerth van Wijk, Roy, Gotua, Maia, Grimshaw, Kate, Grünhagen, Josefine, Heffler, Enrico, Hide, Michihiro, Hoffmann-Sommergruber, Karin, Incorvaia, Cristoforo, Janson, Christer, Malte John, Swen, Jones, Carla, Jutel, Marek, Katoh, Norito, Kendziora, Benjamin, Kinaciyan, Tamar, Knol, Edward, Kurbacheva, Oksana, Lau, Susanne, Loh, Richard, Lombardi, Carlo, Mäkelä, Mika, Marchisotto, Mary Jane, Makris, Michael, Maurer, Marcus, Meyer, Rosan, Mijakoski, Dragan, Minov, Jordan, Mullol, Joaquim, Nilsson, Caroline, Nowak–Wegrzyn, Anna, Nwaru, Bright I., Odemyr, Mikela, Pajno, Giovanni Battista, Paudel, Sushil, Papadopoulos, Nikolaos G., Renz, Harald, Ricci, Giampaolo, Ring, Johannes, Rogala, Barbara, Sampson, Hugh, Senna, Gianenrico, Sitkauskiene, Brigita, Smith, Peter Kenneth, Stevanovic, Katarina, Stoleski, Sasho, Szajewska, Hania, Tanaka, Akio, Todo-Bom, Ana, Topal, Fatih Alexander, Valovirta, Erkka, Van Ree, Ronald, Venter, Carina, Wöhrl, Stefan, Wong, Gary W.K., Zhao, Zuotao, and Worm, Margitta

Abstract

Background: Food anaphylaxis is commonly elicited by unintentional ingestion of foods containing the allergen above the tolerance threshold level of the individual. While labeling the 14 main allergens used as ingredients in food products is mandatory in the EU, there is no legal definition of declaring potential contaminants. Precautionary allergen labeling such as “may contain traces of” is often used. However, this is unsatisfactory for consumers as they get no information if the contamination is below their personal threshold. In discussions with the food industry and technologists, it was suggested to use a voluntary declaration indicating that all declared contaminants are below a threshold of 0.5 mg protein per 100 g of food. This concentration is known to be below the threshold of most patients, and it can be technically guaranteed in most food production. However, it was also important to assess that in case of accidental ingestion of contaminants below this threshold by highly allergic patients, no fatal anaphylactic reaction could occur. Therefore, we performed a systematic review to assess whether a fatal reaction to 5mg of protein or less has been reported, assuming that a maximum portion size of 1kg of a processed food exceeds any meal and thus gives a sufficient safety margin. Methods: MEDLINE and EMBASE were searched until 24 January 2021 for provocation studies and case reports in which one of the 14 major food allergens was reported to elicit fatal or life-threatening anaphylactic reactions and assessed if these occurred below the ingestion of 5mg of protein. A Delphi process was performed to obtain an expert consensus on the results. Results: In the 210 studies included, in our search, no reports of fatal anaphylactic reactions reported below 5 mg protein ingested were identified. However, in provocation studies and case reports, severe reactions below 5 mg were reported for the following allergens: eggs, fish, lupin, milk, nuts, peanuts, soy

Published
2022

40. One hundred and ten years of Allergen Immunotherapy:A journey from empiric observation to evidence

Author

Pfaar, Oliver, Bousquet, Jean, Durham, Stephen R., Kleine-Tebbe, Jörg, Larché, Mark, Roberts, Graham, Shamji, Mohamed H., Gerth van Wijk, Roy, Pfaar, Oliver, Bousquet, Jean, Durham, Stephen R., Kleine-Tebbe, Jörg, Larché, Mark, Roberts, Graham, Shamji, Mohamed H., and Gerth van Wijk, Roy

Abstract

One hundred and ten years after Noon's first clinical report of the subcutaneous application of allergen extracts, allergen immunotherapy (AIT) has evolved as the most important pillar of the treatment of allergic patients. It is the only disease-modifying treatment option available and the evidence for its clinical efficacy and safety is broad and undisputed. Throughout recent decades, more insights into the underlying mechanisms, in particular the modulation of innate and adaptive immune responses, have been described. AIT is acknowledged by worldwide regulatory authorities, and following the regulatory guidelines for product development, AIT products are subject to a rigorous evaluation before obtaining market authorization. Knowledge and practice are anchored in international guidelines, such as the recently published series of the European Academy of Allergy and Clinical Immunology (EAACI). Innovative approaches continue to be further developed with the focus on clinical improvement by, for example, the usage of adjuvants, peptides, recombinants, modification of allergens, new routes of administration, and the concomitant use of biologicals. In addition, real-life data provide complementary and valuable information on the effectiveness and tolerability of this treatment option in the clinical routine. New mobile health technologies and big-data approaches will improve daily treatment convenience, adherence, and efficacy of AIT. However, the current coronavirus disease 2019 (COVID-19) pandemic has also had some implications for the feasibility and practicability of AIT. Taken together, AIT as the only disease-modifying therapy in allergic diseases has been broadly investigated over the past 110 years laying the path for innovations and further improvement.

Published
2022

41. Proposal of 0.5 mg of protein/100 g of processed food as threshold for voluntary declaration of food allergen traces in processed food—A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GA²LEN position paper

Author

CTI Research, MS Dermatologie/Allergologie, Infection & Immunity, Zuberbier, Torsten, Dörr, Tamara, Aberer, Werner, Alvaro, Montserrat, Angier, Elizabeth, Arasi, Stefania, Arshad, Hasan, Ballmer-Weber, Barbara, Bartra, Joan, Beck, Lisa, Bégin, Philippe, Bindslev-Jensen, Carsten, Bislimovska, Jovanka, Bousquet, Jean, Brockow, Knut, Bush, Andrew, Cianferoni, Antonella, Cork, Michael J, Custovic, Adnan, Darsow, Ulf, de Jong, Nicolette, Deleanu, Diana, Del Giacco, Stefano, Deschildre, Antoine, Dunn Galvin, Audrey, Ebisawa, Motohiro, Fernández-Rivas, Montserrat, Ferrer, Marta, Fiocchi, Alessandro, Gerth van Wijk, Roy, Gotua, Maia, Grimshaw, Kate, Grünhagen, Josefine, Heffler, Enrico, Hide, Michihiro, Hoffmann-Sommergruber, Karin, Incorvaia, Cristoforo, Janson, Christer, Malte John, Swen, Jones, Carla, Jutel, Marek, Katoh, Norito, Kendziora, Benjamin, Kinaciyan, Tamar, Knol, Edward, Kurbacheva, Oksana, Lau, Susanne, Loh, Richard, Lombardi, Carlo, Mäkelä, Mika, Marchisotto, Mary Jane, Makris, Michael, Maurer, Marcus, Meyer, Rosan, Mijakoski, Dragan, Minov, Jordan, Mullol, Joaquim, Nilsson, Caroline, Nowak-Wegrzyn, Anna, Nwaru, Bright I, Odemyr, Mikela, Pajno, Giovanni Battista, Paudel, Sushil, Papadopoulos, Nikolaos G, Renz, Harald, Ricci, Giampaolo, Ring, Johannes, Rogala, Barbara, Sampson, Hugh, Senna, Gianenrico, Sitkauskiene, Brigita, Smith, Peter Kenneth, Stevanovic, Katarina, Stoleski, Sasho, Szajewska, Hania, Tanaka, Akio, Todo-Bom, Ana, Topal, Fatih Alexander, Valovirta, Erkka, Van Ree, Ronald, Venter, Carina, Wöhrl, Stefan, Wong, Gary W K, Zhao, Zuotao, Worm, Margitta, CTI Research, MS Dermatologie/Allergologie, Infection & Immunity, Zuberbier, Torsten, Dörr, Tamara, Aberer, Werner, Alvaro, Montserrat, Angier, Elizabeth, Arasi, Stefania, Arshad, Hasan, Ballmer-Weber, Barbara, Bartra, Joan, Beck, Lisa, Bégin, Philippe, Bindslev-Jensen, Carsten, Bislimovska, Jovanka, Bousquet, Jean, Brockow, Knut, Bush, Andrew, Cianferoni, Antonella, Cork, Michael J, Custovic, Adnan, Darsow, Ulf, de Jong, Nicolette, Deleanu, Diana, Del Giacco, Stefano, Deschildre, Antoine, Dunn Galvin, Audrey, Ebisawa, Motohiro, Fernández-Rivas, Montserrat, Ferrer, Marta, Fiocchi, Alessandro, Gerth van Wijk, Roy, Gotua, Maia, Grimshaw, Kate, Grünhagen, Josefine, Heffler, Enrico, Hide, Michihiro, Hoffmann-Sommergruber, Karin, Incorvaia, Cristoforo, Janson, Christer, Malte John, Swen, Jones, Carla, Jutel, Marek, Katoh, Norito, Kendziora, Benjamin, Kinaciyan, Tamar, Knol, Edward, Kurbacheva, Oksana, Lau, Susanne, Loh, Richard, Lombardi, Carlo, Mäkelä, Mika, Marchisotto, Mary Jane, Makris, Michael, Maurer, Marcus, Meyer, Rosan, Mijakoski, Dragan, Minov, Jordan, Mullol, Joaquim, Nilsson, Caroline, Nowak-Wegrzyn, Anna, Nwaru, Bright I, Odemyr, Mikela, Pajno, Giovanni Battista, Paudel, Sushil, Papadopoulos, Nikolaos G, Renz, Harald, Ricci, Giampaolo, Ring, Johannes, Rogala, Barbara, Sampson, Hugh, Senna, Gianenrico, Sitkauskiene, Brigita, Smith, Peter Kenneth, Stevanovic, Katarina, Stoleski, Sasho, Szajewska, Hania, Tanaka, Akio, Todo-Bom, Ana, Topal, Fatih Alexander, Valovirta, Erkka, Van Ree, Ronald, Venter, Carina, Wöhrl, Stefan, Wong, Gary W K, Zhao, Zuotao, and Worm, Margitta

Published
2022

42. Proposal of 0.5 mg of protein/100 g of processed food as threshold for voluntary declaration of food allergen traces in processed food—A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GA²LEN position paper

Author

Zuberbier, Torsten; https://orcid.org/0000-0002-1466-8875, Dörr, Tamara, Aberer, Werner, Alvaro, Montserrat; https://orcid.org/0000-0002-5528-8043, Angier, Elizabeth, Arasi, Stefania; https://orcid.org/0000-0002-8135-0568, Arshad, Hasan; https://orcid.org/0000-0001-5988-235X, Ballmer-Weber, Barbara; https://orcid.org/0000-0002-4136-5036, Bartra, Joan; https://orcid.org/0000-0001-7767-4730, Beck, Lisa; https://orcid.org/0000-0002-8452-667X, Bégin, Philippe; https://orcid.org/0000-0002-9089-4604, Bindslev‐Jensen, Carsten; https://orcid.org/0000-0002-8940-038X, Bislimovska, Jovanka, Bousquet, Jean; https://orcid.org/0000-0002-4061-4766, Brockow, Knut; https://orcid.org/0000-0002-2775-3681, Bush, Andrew; https://orcid.org/0000-0001-6756-9822, Cianferoni, Antonella; https://orcid.org/0000-0002-2966-2564, Cork, Michael J; https://orcid.org/0000-0003-4428-2428, Custovic, Adnan; https://orcid.org/0000-0001-5218-7071, Darsow, Ulf, de Jong, Nicolette, Deleanu, Diana, Del Giacco, Stefano; https://orcid.org/0000-0002-4517-1749, Deschildre, Antoine; https://orcid.org/0000-0003-2006-7221, Dunn Galvin, Audrey, Ebisawa, Motohiro; https://orcid.org/0000-0003-4117-558X, Fernández‐Rivas, Montserrat; https://orcid.org/0000-0003-1748-2328, Ferrer, Marta; https://orcid.org/0000-0001-8495-1302, Fiocchi, Alessandro; https://orcid.org/0000-0002-2549-0523, Gerth van Wijk, Roy; https://orcid.org/0000-0002-9608-8742, et al, Zuberbier, Torsten; https://orcid.org/0000-0002-1466-8875, Dörr, Tamara, Aberer, Werner, Alvaro, Montserrat; https://orcid.org/0000-0002-5528-8043, Angier, Elizabeth, Arasi, Stefania; https://orcid.org/0000-0002-8135-0568, Arshad, Hasan; https://orcid.org/0000-0001-5988-235X, Ballmer-Weber, Barbara; https://orcid.org/0000-0002-4136-5036, Bartra, Joan; https://orcid.org/0000-0001-7767-4730, Beck, Lisa; https://orcid.org/0000-0002-8452-667X, Bégin, Philippe; https://orcid.org/0000-0002-9089-4604, Bindslev‐Jensen, Carsten; https://orcid.org/0000-0002-8940-038X, Bislimovska, Jovanka, Bousquet, Jean; https://orcid.org/0000-0002-4061-4766, Brockow, Knut; https://orcid.org/0000-0002-2775-3681, Bush, Andrew; https://orcid.org/0000-0001-6756-9822, Cianferoni, Antonella; https://orcid.org/0000-0002-2966-2564, Cork, Michael J; https://orcid.org/0000-0003-4428-2428, Custovic, Adnan; https://orcid.org/0000-0001-5218-7071, Darsow, Ulf, de Jong, Nicolette, Deleanu, Diana, Del Giacco, Stefano; https://orcid.org/0000-0002-4517-1749, Deschildre, Antoine; https://orcid.org/0000-0003-2006-7221, Dunn Galvin, Audrey, Ebisawa, Motohiro; https://orcid.org/0000-0003-4117-558X, Fernández‐Rivas, Montserrat; https://orcid.org/0000-0003-1748-2328, Ferrer, Marta; https://orcid.org/0000-0001-8495-1302, Fiocchi, Alessandro; https://orcid.org/0000-0002-2549-0523, Gerth van Wijk, Roy; https://orcid.org/0000-0002-9608-8742, and et al

Published
2022

43. Proposal of 0.5 mg of protein/100 g of processed food as threshold for voluntary declaration of food allergen traces in processed food—A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GA²LEN position paper

Author

Zuberbier, Torsten, Dörr, Tamara, Aberer, Werner, Alvaro, Montserrat, Angier, Elizabeth, Arasi, Stefania, Arshad, Hasan, Ballmer-Weber, Barbara, Bartra, Joan, Beck, Lisa, Bégin, Philippe, Bindslev‐Jensen, Carsten, Bislimovska, Jovanka, Bousquet, Jean, Brockow, Knut, Bush, Andrew, Cianferoni, Antonella, Cork, Michael J, Custovic, Adnan, Darsow, Ulf, de Jong, Nicolette, Deleanu, Diana, Del Giacco, Stefano, Deschildre, Antoine, Dunn Galvin, Audrey, Ebisawa, Motohiro, Fernández‐Rivas, Montserrat, Ferrer, Marta, Fiocchi, Alessandro, Gerth van Wijk, Roy, et al, University of Zurich, and Zuberbier, Torsten

Subjects
2403 Immunology, Immunology, 2723 Immunology and Allergy, 10177 Dermatology Clinic, Immunology and Allergy, 610 Medicine & health
Published
2022
Full Text
View/download PDF

45. Introduction of Heated Cow’s Milk Protein in Challenge-Proven Cow’s Milk Allergic Children: The iAGE Study

Author

de Jong, Nicolette W., primary, van Splunter, Marloes E., additional, Emons, Joyce A. M., additional, Hettinga, Kasper A., additional, Gerth van Wijk, Roy, additional, Wichers, Harry J., additional, Savelkoul, Huub F. J., additional, Sprikkelman, Aline B., additional, van Neerven, R. J. Joost, additional, Liu, Liu, additional, van der Meulen, Gerbrich, additional, Herpertz, Irene, additional, Duijvestijn, Yvonne C. M., additional, Breukels, Mijke, additional, Brouwer, Marianne I., additional, Schilperoord, Jaap, additional, van Doorn, Olga, additional, Vlieg-Boerstra, Berber, additional, van den Berg, Jochum, additional, Pellis, Linette, additional, Terlouw, Severina, additional, Hendriks, Astrid I., additional, Schreurs, Marco W. J., additional, van Boven, Frank E., additional, and Arends, Nicolette J. T., additional

Published
2022
Full Text
View/download PDF

46. Development and validation of combined symptom‐medication scores for allergic rhinitis*

Author

Sousa‐Pinto, Bernardo, primary, Azevedo, Luís Filipe, additional, Jutel, Marek, additional, Agache, Ioana, additional, Canonica, G. Walter, additional, Czarlewski, Wienczyslawa, additional, Papadopoulos, Nikolaos G., additional, Bergmann, Karl‐Christian, additional, Devillier, Philippe, additional, Laune, Daniel, additional, Klimek, Ludger, additional, Anto, Aram, additional, Anto, Josep M., additional, Eklund, Patrik, additional, Almeida, Rute, additional, Bedbrook, Anna, additional, Bosnic‐Anticevich, Sinthia, additional, Brough, Helen A., additional, Brussino, Luisa, additional, Cardona, Victoria, additional, Casale, Thomas, additional, Cecchi, Lorenzo, additional, Charpin, Denis, additional, Chivato, Tomás, additional, Costa, Elisio M., additional, Cruz, Alvaro A., additional, Dramburg, Stephanie, additional, Durham, Stephen R., additional, De Feo, Giulia, additional, Gerth van Wijk, Roy, additional, Fokkens, Wystke J., additional, Gemicioglu, Bilun, additional, Haahtela, Tari, additional, Illario, Maddalena, additional, Ivancevich, Juan Carlos, additional, Kvedariene, Violeta, additional, Kuna, Piotr, additional, Larenas‐Linnemann, Désirée E., additional, Makris, Michael, additional, Mathieu‐Dupas, Eve, additional, Melén, Erik, additional, Morais‐Almeida, Mario, additional, Mösges, Ralph, additional, Mullol, Joaquim, additional, Nadeau, Kari C., additional, Pham‐Thi, Nhân, additional, O’Hehir, Robyn, additional, Regateiro, Frederico S., additional, Reitsma, Sietze, additional, Samolinski, Boleslaw, additional, Sheikh, Aziz, additional, Stellato, Cristiana, additional, Todo‐Bom, Ana, additional, Tomazic, Peter Valentin, additional, Toppila‐Salmi, Sanna, additional, Valero, Antonio, additional, Valiulis, Arunas, additional, Ventura, Maria Teresa, additional, Wallace, Dana, additional, Waserman, Susan, additional, Yorgancioglu, Arzu, additional, De Vries, Govert, additional, van Eerd, Michiel, additional, Zieglmayer, Petra, additional, Zuberbier, Torsten, additional, Pfaar, Oliver, additional, Almeida Fonseca, João, additional, and Bousquet, Jean, additional

Published
2022
Full Text
View/download PDF

47. Pollen season is reflected on symptom load for grass and birch pollen‐induced allergic rhinitis in different geographic areas—An EAACI Task Force Report

Author

Pfaar, Oliver, Karatzas, Kostas, Bastl, Katharina, Berger, Uwe, Buters, Jeroen, Darsow, Ulf, Demoly, Pascal, Durham, Stephen, Galán, Carmen, Gehrig, Regula, Gerth Van Wijk, Roy, Jacobsen, Lars, Katsifarakis, Nikos, Klimek, Ludger, Saarto, Annika, Sofiev, Mikhail, Thibaudon, Michel, Werchan, Barbora, Bergmann, Karl-Christian, Bergmann, Karl‐Christian, Center for Rhinology and Allergology Wiesbaden, University Hospital Mannheim, Aristotle University of Thessaloniki, Institut für Paläontologie, Institute of Psychosocial Medicine and Psychotherapy, Jena University Hospital, Friedrich Schiller University Jena, Center of Allergy & Environment (CK-CARE, ZAUM), Helmholtz-Zentrum München (HZM), Department of Dermatology and Allergy Biederstein, Technische Universität Munchen - Université Technique de Munich [Munich, Allemagne] (TUM), Département pneumologie et addictologie [Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Arnaud de Villeneuve, Imperial College London, University of Extremadura, Section of Allergology, Erasmus Medical Centre, Allergy Learning and Consulting, Zentrum für Rhinologie und Allergologie [Wiesbaden, Germany], Finnish Meteorological Institute (FMI), Réseau National de Surveillance Aérobiologique (RNSA), Secretary General of the Global Allergy and Asthma European Network (GA2LEN), and Charité - UniversitätsMedizin = Charité - University Hospital [Berlin]

Subjects
0301 basic medicine, Allergen immunotherapy, Allergy, peak pollen period, Immunology, Biology, Poaceae, medicine.disease_cause, geographic differences, 03 medical and health sciences, 0302 clinical medicine, Germany, Grass pollen, Pollen, otorhinolaryngologic diseases, medicine, Humans, Immunology and Allergy, Statistical analysis, [SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology, Betula, Finland, pollen season, allergic rhinitis, Pollen season, Task force, food and beverages, pollen concentration, Allergens, medicine.disease, Rhinitis, Allergic, ddc, Europe, Birch pollen, 030104 developmental biology, 030228 respiratory system, Austria, allergen immunotherapy, France, Seasons, Demography
Abstract

Background The effectiveness of allergen immunotherapy (AIT) in seasonal and perennial allergic rhinitis (AR) depends on the definition of pollen exposure intensity or time period. We recently evaluated pollen and symptom data from Germany to examine the new definitions of the European Academy of Allergy and Clinical Immunology (EAACI) on pollen season and peak pollen period start and end. Now, we aim to confirm the feasibility of these definitions to properly mirror symptom loads for grass and birch pollen-induced allergic rhinitis in other European geographical areas such as Austria, Finland and France, and therefore their suitability for AIT and clinical practice support. Methods Data from twenty-three pollen monitoring stations from three countries in Europe and for 3 years (2014-2016) were used to investigate the correlation between birch and grass pollen concentrations during the birch and grass pollen season defined via the EAACI criteria, and total nasal symptom and medication scores as reported with the aid of the patient's hay-fever diary (PHD). In addition, we conducted a statistical analysis, together with a graphical investigation, to reveal correlations and dependencies between the studied parameters. Results The analysis demonstrated that the definitions of pollen season as well as peak pollen period start and end as proposed by the EAACI are correlated to pollen-induced symptom loads reported by PHD users during birch and grass pollen season. A statistically significant correlation (slightly higher for birch) has been found between the Total Nasal Symptom and Medication Score (TNSMS) and the pollen concentration levels. Moreover, the maximum symptom levels occurred mostly within the peak pollen periods (PPP) following the EAACI criteria. Conclusions Based on our analyses, we confirm the validity of the EAACI definitions on pollen season for both birch and grass and for a variety of geographical locations for the four European countries (including Germany from a previous publication) analyzed so far. On this basis, the use of the EAACI definitions is supported in future clinical trials on AIT as well as in daily routine for optimal patient care. Further evaluation of the EAACI criteria in other European regions is recommended.

Published
2020
Full Text
View/download PDF

48. Erratum to "IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position paper" [World Allergy Organ J 13/2 (2020) 100080]

Author

Ansotegui, Ignacio J., Melioli, Giovanni, Canonica, Giorgio Walter, Caraballo, Luis, Villa, Elisa, Ebisawa, Motohiro, Passalacqua, Giovanni, Savi, Eleonora, Ebo, Didier, Gómez, R.Maximiliano, Luengo Sánchez, Olga, Oppenheimer, John J., Jensen-Jarolim, Erika, Fischer, David A., Haahtela, Tari, Antila, Martti, Bousquet, Jean J., Cardona, Victoria, Chiang, Wen Chin, Demoly, Pascal M., DuBuske, Lawrence M., Ferrer Puga, Marta, Gerth van Wijk, Roy, González Díaz, Sandra Nora, Gonzalez-Estrada, Alexei, Jares, Edgardo, Kalpaklioğlu, Ayse Füsun, Kase Tanno, Luciana, Kowalski, Marek L., Ledford, Dennis K., Monge Ortega, Olga Patricia, Morais-Almeida, Mário, Pfaar, Oliver, Poulsen, Lars K., Pawankar, Ruby, Renz, Harald E., Romano, Antonino G., Rosário Filho, Nelson A., Rosenwasser, Lanny, Sánchez Borges, Mario A., Scala, Enrico, Senna, Gian-Enrico, Sisul, Juan Carlos, Tang, Mimi L.K., Yu-Hor Thong, Bernard, Valenta, Rudolf, Wood, Robert A., and Zuberbier, Torsten

Published
2021
Full Text
View/download PDF

49. Proposal of 0.5 mg of protein/100 g of processed food as threshold for voluntary declaration of food allergen traces in processed food—A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GA²LEN position paper

Author

Zuberbier, Torsten, primary, Dörr, Tamara, additional, Aberer, Werner, additional, Alvaro, Montserrat, additional, Angier, Elizabeth, additional, Arasi, Stefania, additional, Arshad, Hasan, additional, Ballmer‐Weber, Barbara, additional, Bartra, Joan, additional, Beck, Lisa, additional, Bégin, Philippe, additional, Bindslev‐Jensen, Carsten, additional, Bislimovska, Jovanka, additional, Bousquet, Jean, additional, Brockow, Knut, additional, Bush, Andrew, additional, Cianferoni, Antonella, additional, Cork, Michael J., additional, Custovic, Adnan, additional, Darsow, Ulf, additional, Jong, Nicolette, additional, Deleanu, Diana, additional, Del Giacco, Stefano, additional, Deschildre, Antoine, additional, Dunn Galvin, Audrey, additional, Ebisawa, Motohiro, additional, Fernández‐Rivas, Montserrat, additional, Ferrer, Marta, additional, Fiocchi, Alessandro, additional, Gerth van Wijk, Roy, additional, Gotua, Maia, additional, Grimshaw, Kate, additional, Grünhagen, Josefine, additional, Heffler, Enrico, additional, Hide, Michihiro, additional, Hoffmann‐Sommergruber, Karin, additional, Incorvaia, Cristoforo, additional, Janson, Christer, additional, Malte John, Swen, additional, Jones, Carla, additional, Jutel, Marek, additional, Katoh, Norito, additional, Kendziora, Benjamin, additional, Kinaciyan, Tamar, additional, Knol, Edward, additional, Kurbacheva, Oksana, additional, Lau, Susanne, additional, Loh, Richard, additional, Lombardi, Carlo, additional, Mäkelä, Mika, additional, Marchisotto, Mary Jane, additional, Makris, Michael, additional, Maurer, Marcus, additional, Meyer, Rosan, additional, Mijakoski, Dragan, additional, Minov, Jordan, additional, Mullol, Joaquim, additional, Nilsson, Caroline, additional, Nowak–Wegrzyn, Anna, additional, Nwaru, Bright I., additional, Odemyr, Mikela, additional, Pajno, Giovanni Battista, additional, Paudel, Sushil, additional, Papadopoulos, Nikolaos G., additional, Renz, Harald, additional, Ricci, Giampaolo, additional, Ring, Johannes, additional, Rogala, Barbara, additional, Sampson, Hugh, additional, Senna, Gianenrico, additional, Sitkauskiene, Brigita, additional, Smith, Peter Kenneth, additional, Stevanovic, Katarina, additional, Stoleski, Sasho, additional, Szajewska, Hania, additional, Tanaka, Akio, additional, Todo‐Bom, Ana, additional, Topal, Fatih Alexander, additional, Valovirta, Erkka, additional, Van Ree, Ronald, additional, Venter, Carina, additional, Wöhrl, Stefan, additional, Wong, Gary W.K., additional, Zhao, Zuotao, additional, and Worm, Margitta, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results